AR012358A1 - Formulaciones de liberacion prolongada de derivados de eritromicina y su uso para la manufactura de un medicamento - Google Patents
Formulaciones de liberacion prolongada de derivados de eritromicina y su uso para la manufactura de un medicamentoInfo
- Publication number
- AR012358A1 AR012358A1 ARP980101591A ARP980101591A AR012358A1 AR 012358 A1 AR012358 A1 AR 012358A1 AR P980101591 A ARP980101591 A AR P980101591A AR P980101591 A ARP980101591 A AR P980101591A AR 012358 A1 AR012358 A1 AR 012358A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- erythromycin derivative
- prolonged release
- formulations
- manufacture
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Abstract
Se descubre una composicion farmacéutica para liberacion prolongada de un derivado de eritromicina en el medio ambiente gastrointestinal. Lacomposicion comprende un derivado de eritromicina y un polímero farmacéuticamenteacep table, de manera que, cuando se ingiere en forma oral,la composicion induce un C(max) estadísticamente significantemente menor en el plasma que una composicion de liberacion inmediata del derivado deeritromicina, mientras que mantiene labiodispo nibilidad y concentracion mínima substancialmente equivalente a la de la composicion de liberacion inmediatadel derivado de eritromicina, con la dosificacion multiple. Las composiciones de la invencion tienen un perfil de saborperfeccionado, y red ucidos efectoscolaterales gastrointestinales, en comparacion con aquéllos para la composicion de liberacion inmediata
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/838,900 US6010718A (en) | 1997-04-11 | 1997-04-11 | Extended release formulations of erythromycin derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
AR012358A1 true AR012358A1 (es) | 2000-10-18 |
Family
ID=25278344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980101591A AR012358A1 (es) | 1997-04-11 | 1998-04-07 | Formulaciones de liberacion prolongada de derivados de eritromicina y su uso para la manufactura de un medicamento |
Country Status (29)
Country | Link |
---|---|
US (1) | US6010718A (es) |
EP (2) | EP1340495B1 (es) |
JP (2) | JP4394754B2 (es) |
KR (1) | KR100484559B1 (es) |
CN (1) | CN100408044C (es) |
AR (1) | AR012358A1 (es) |
AT (1) | ATE253371T1 (es) |
AU (1) | AU737324B2 (es) |
BG (1) | BG65188B1 (es) |
BR (1) | BR9807974A (es) |
CA (1) | CA2285266C (es) |
CO (1) | CO4940403A1 (es) |
CZ (1) | CZ294333B6 (es) |
DE (1) | DE69819481T2 (es) |
DK (1) | DK0973527T3 (es) |
ES (1) | ES2205454T3 (es) |
HK (1) | HK1027023A1 (es) |
HU (1) | HUP0001382A3 (es) |
IL (3) | IL131616A0 (es) |
NO (1) | NO994946L (es) |
NZ (3) | NZ596215A (es) |
PL (2) | PL402949A1 (es) |
PT (1) | PT973527E (es) |
SA (1) | SA98190065B1 (es) |
SK (2) | SK288109B6 (es) |
TR (2) | TR199902149T2 (es) |
TW (1) | TW576743B (es) |
WO (1) | WO1998046239A1 (es) |
ZA (1) | ZA982916B (es) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU773863B2 (en) * | 1997-04-11 | 2004-06-10 | Bgp Products Operations Gmbh | Extended release formulations of erythromycin derivatives |
US6551616B1 (en) * | 1997-04-11 | 2003-04-22 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
US6099859A (en) | 1998-03-20 | 2000-08-08 | Andrx Pharmaceuticals, Inc. | Controlled release oral tablet having a unitary core |
TR200000054A2 (tr) * | 2000-01-05 | 2001-08-21 | Sanovel İlaç San. Ve Ti̇c. Anoni̇m Şi̇rketi̇ | Klaritromisin içeren sürekli salım sağlayan tablet formülasyonları. |
US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US6565882B2 (en) * | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
WO2001064224A1 (en) * | 2000-02-29 | 2001-09-07 | Teva Pharmaceutical Industries Ltd. | Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same |
DE60138876D1 (de) * | 2000-03-28 | 2009-07-16 | Sandoz Ag | Geschmackmaskierte granulierte teilchen |
IN192748B (es) * | 2000-08-29 | 2004-05-15 | Ranbaxy Lab Ltd | |
US20020068078A1 (en) * | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
US6541014B2 (en) * | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
MXPA03003146A (es) * | 2000-10-13 | 2004-12-06 | Advancis Pharmaceuticals | Derivados de eritromicina de liberacion prolongada. |
US6866866B1 (en) | 2000-11-03 | 2005-03-15 | Andrx Labs, Llc | Controlled release metformin compositions |
US6790459B1 (en) | 2000-11-03 | 2004-09-14 | Andrx Labs, Llc | Methods for treating diabetes via administration of controlled release metformin |
US20060034922A1 (en) * | 2000-11-03 | 2006-02-16 | Andrx Labs, Llc | Controlled release metformin compositions |
US20020197314A1 (en) * | 2001-02-23 | 2002-12-26 | Rudnic Edward M. | Anti-fungal composition |
WO2003017981A1 (en) | 2001-08-29 | 2003-03-06 | Ranbaxy Laboratories Limited | Controlled release formulation of clarithromycin or tinidazol |
EP1423097A1 (en) * | 2001-08-29 | 2004-06-02 | Ranbaxy Laboratories, Ltd. | Controlled release formulation of clarithromycin or tinidazol |
US20050233003A1 (en) * | 2001-09-28 | 2005-10-20 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid |
US6878693B2 (en) * | 2001-09-28 | 2005-04-12 | Solubest Ltd. | Hydrophilic complexes of lipophilic materials and an apparatus and method for their production |
US20050249786A1 (en) * | 2001-09-28 | 2005-11-10 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds |
US20050227911A1 (en) * | 2001-09-28 | 2005-10-13 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules |
US20050191359A1 (en) * | 2001-09-28 | 2005-09-01 | Solubest Ltd. | Water soluble nanoparticles and method for their production |
WO2003037304A1 (en) * | 2001-11-02 | 2003-05-08 | Wockhardt Limited | Controlled release compositions for macrolide antimicrobial agents |
US7700851B2 (en) * | 2001-11-13 | 2010-04-20 | U.S. Smokeless Tobacco Company | Tobacco nicotine demethylase genomic clone and uses thereof |
CA2479350A1 (en) * | 2002-03-15 | 2003-09-25 | Cypress Bioscience, Inc. | Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes |
WO2003099214A2 (en) * | 2002-05-23 | 2003-12-04 | Andrx Corporation | Biguanide formulations |
WO2003105810A1 (en) * | 2002-06-14 | 2003-12-24 | Andrx Corporation | Pharmaceutical compositions for drugs having ph-dependentsolubility |
US20040121010A1 (en) * | 2002-10-25 | 2004-06-24 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
US20060003004A1 (en) * | 2002-10-25 | 2006-01-05 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
US9561182B2 (en) * | 2003-08-22 | 2017-02-07 | Cure Pharmaceutical Corporation | Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals |
US20040131662A1 (en) | 2003-11-12 | 2004-07-08 | Davidson Robert S. | Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films |
US20040191302A1 (en) | 2003-03-28 | 2004-09-30 | Davidson Robert S. | Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films |
US8999372B2 (en) * | 2002-11-14 | 2015-04-07 | Cure Pharmaceutical Corporation | Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use |
JP2006515008A (ja) * | 2003-01-28 | 2006-05-18 | コレギウム ファーマシューティカル, インコーポレイテッド | 経口投与のためのミルナシプランの多粒子状組成物 |
US20040185097A1 (en) * | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
CA2524827A1 (en) * | 2003-05-06 | 2004-11-25 | Nirmal Mulye | Controlled release formulation of erythromycin derivatives |
US7063862B2 (en) * | 2003-06-03 | 2006-06-20 | Biokey, Inc. | Pharmaceutical composition and method for treating |
CA2673334C (en) * | 2003-06-16 | 2013-11-12 | Andrx Pharmaceuticals, Llc | Oral extended-release composition |
US20050053658A1 (en) * | 2003-09-09 | 2005-03-10 | Venkatesh Gopi M. | Extended release systems for macrolide antibiotics |
CA2533292C (en) * | 2003-07-21 | 2013-12-31 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
EP1648418A4 (en) * | 2003-07-21 | 2011-11-16 | Middlebrook Pharmaceuticals Inc | ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION |
AU2004258949B2 (en) * | 2003-07-21 | 2011-02-10 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
CA2535177A1 (en) * | 2003-08-11 | 2005-02-24 | Advancis Pharmaceutical Corporation | Robust pellet |
EP1653924A4 (en) | 2003-08-12 | 2009-09-09 | Middlebrook Pharmaceuticals In | ANTIBIOTICS, USE AND FORMULATION ASSOCIATED |
CA2535780A1 (en) * | 2003-08-29 | 2005-03-17 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
WO2005023221A1 (en) * | 2003-09-05 | 2005-03-17 | Ranbaxy Laboratories Limited | Clarithromycin formulations having improved biovailability |
US8460710B2 (en) * | 2003-09-15 | 2013-06-11 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
US20050084540A1 (en) * | 2003-10-17 | 2005-04-21 | Indranil Nandi | Taste masking antibiotic composition |
US8168228B2 (en) * | 2003-10-17 | 2012-05-01 | Sandoz Ag | Antibiotic clarithromycin micropellet compositions |
WO2005044262A1 (en) | 2003-10-29 | 2005-05-19 | Wyeth | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof |
US20050101547A1 (en) * | 2003-11-06 | 2005-05-12 | Sadatrezaei Mohsen | Stabilized azithromycin composition |
CN1889932A (zh) * | 2003-12-04 | 2007-01-03 | 辉瑞产品公司 | 制备药用多颗粒的方法 |
WO2005053652A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
CA2547597A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate compositions with improved stability |
MXPA06005913A (es) * | 2003-12-04 | 2006-06-27 | Pfizer Prod Inc | Formas de dosificacion de multiparticulas de azitromicina por procedimientos basados en liquidos. |
US6984403B2 (en) * | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
WO2005053639A2 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Controlled release multiparticulates formed with dissolution enhancers |
EP1689368B1 (en) * | 2003-12-04 | 2016-09-28 | Bend Research, Inc | Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions |
CN1889931A (zh) * | 2003-12-04 | 2007-01-03 | 辉瑞产品公司 | 利用挤压器制备优选含泊洛沙姆和甘油酯的多重粒子阿奇霉素组合物的喷雾-冻凝方法 |
US7943585B2 (en) | 2003-12-22 | 2011-05-17 | Sandoz, Inc. | Extended release antibiotic composition |
JP2007517039A (ja) * | 2003-12-24 | 2007-06-28 | アドバンシス ファーマスーティカル コーポレイション | 変性放出製剤の吸収増強 |
MXPA06010805A (es) * | 2004-03-24 | 2006-12-19 | Lupin Ltd | Formulacion de claritromicina de libracion prolongada. |
US20050260263A1 (en) * | 2004-05-18 | 2005-11-24 | Panion & Bf Biotech Inc. | Sustained release formulation for sparingly soluble main drugs |
KR101122096B1 (ko) * | 2004-05-20 | 2012-03-15 | 주식회사종근당 | 쓴맛을 차폐하면서 우수한 용출률을 보이는클라리스로마이신의 약제학적 조성물 및 그의 제조 방법 |
KR100621342B1 (ko) * | 2004-06-22 | 2006-09-18 | (주)다산메디켐 | 클래리스로마이신-함유 약제학적 조성물 및 그의 제조방법 |
CA2572292A1 (en) * | 2004-07-02 | 2006-02-09 | Advancis Pharmaceutical Corporation | Tablet for pulsed delivery |
US8778924B2 (en) * | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
JPWO2007126039A1 (ja) * | 2006-04-28 | 2009-09-10 | 塩野義製薬株式会社 | マクロライド系抗生物質の被覆製剤 |
US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
US20070281894A1 (en) * | 2006-06-05 | 2007-12-06 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted erythromycin analogs |
EP2283824B1 (en) | 2009-07-30 | 2017-04-19 | Special Products Line S.p.A. | Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin |
EP2671571A1 (en) | 2012-06-05 | 2013-12-11 | Sanovel Ilac Sanayi ve Ticaret A.S. | Controlled-release formulations of clarithromycin |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3870790A (en) * | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
US4226849A (en) * | 1979-06-14 | 1980-10-07 | Forest Laboratories Inc. | Sustained release therapeutic compositions |
US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
ATE66143T1 (de) * | 1985-01-11 | 1991-08-15 | Abbott Lab | Feste zubereitung mit langsamer freisetzung. |
FR2585948B1 (fr) * | 1985-08-06 | 1988-12-16 | Pf Medicament | Procede de fabrication de comprimes d'indometacine |
US4808411A (en) * | 1987-06-05 | 1989-02-28 | Abbott Laboratories | Antibiotic-polymer compositions |
US4925675A (en) | 1988-08-19 | 1990-05-15 | Himedics, Inc. | Erythromycin microencapsulated granules |
JP3265680B2 (ja) * | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
US5393765A (en) * | 1993-12-13 | 1995-02-28 | Hoffmann-La Roche Inc. | Pharmaceutical compositions with constant erosion volume for zero order controlled release |
RO114740B1 (ro) * | 1994-05-06 | 1999-07-30 | Pfizer | Compozitie cu eliberare controlata, procedeu de obtinere a acesteia si metoda de tratament |
JPH0995440A (ja) * | 1995-09-29 | 1997-04-08 | Roussel Morishita Kk | 徐放性製剤およびその製造方法 |
US5919489A (en) * | 1995-11-01 | 1999-07-06 | Abbott Laboratories | Process for aqueous granulation of clarithromycin |
US5705190A (en) * | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
US5972389A (en) * | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
-
1997
- 1997-04-11 US US08/838,900 patent/US6010718A/en not_active Expired - Lifetime
-
1998
- 1998-03-06 TR TR1999/02149T patent/TR199902149T2/xx unknown
- 1998-03-06 PL PL402949A patent/PL402949A1/pl not_active Application Discontinuation
- 1998-03-06 CN CNB03157906XA patent/CN100408044C/zh not_active Expired - Fee Related
- 1998-03-06 NZ NZ596215A patent/NZ596215A/xx not_active IP Right Cessation
- 1998-03-06 PL PL98336142A patent/PL336142A1/xx not_active IP Right Cessation
- 1998-03-06 NZ NZ537410A patent/NZ537410A/en not_active IP Right Cessation
- 1998-03-06 JP JP54388298A patent/JP4394754B2/ja not_active Expired - Fee Related
- 1998-03-06 AT AT98907722T patent/ATE253371T1/de active
- 1998-03-06 KR KR10-1999-7009335A patent/KR100484559B1/ko not_active IP Right Cessation
- 1998-03-06 NZ NZ337120A patent/NZ337120A/en not_active IP Right Cessation
- 1998-03-06 IL IL13161698A patent/IL131616A0/xx unknown
- 1998-03-06 AU AU63463/98A patent/AU737324B2/en not_active Expired
- 1998-03-06 WO PCT/US1998/004373 patent/WO1998046239A1/en active Application Filing
- 1998-03-06 SK SK1380-99A patent/SK288109B6/sk not_active IP Right Cessation
- 1998-03-06 SK SK5021-2010A patent/SK288127B6/sk not_active IP Right Cessation
- 1998-03-06 BR BR9807974-3A patent/BR9807974A/pt not_active Application Discontinuation
- 1998-03-06 CZ CZ19993471A patent/CZ294333B6/cs not_active IP Right Cessation
- 1998-03-06 PT PT98907722T patent/PT973527E/pt unknown
- 1998-03-06 EP EP03008281.2A patent/EP1340495B1/en not_active Expired - Lifetime
- 1998-03-06 CA CA002285266A patent/CA2285266C/en not_active Expired - Lifetime
- 1998-03-06 HU HU0001382A patent/HUP0001382A3/hu unknown
- 1998-03-06 DE DE69819481T patent/DE69819481T2/de not_active Revoked
- 1998-03-06 TR TR2007/07263T patent/TR200707263T2/xx unknown
- 1998-03-06 ES ES98907722T patent/ES2205454T3/es not_active Expired - Lifetime
- 1998-03-06 DK DK98907722T patent/DK0973527T3/da active
- 1998-03-06 EP EP98907722A patent/EP0973527B1/en not_active Revoked
- 1998-03-17 TW TW087103954A patent/TW576743B/zh not_active IP Right Cessation
- 1998-04-06 ZA ZA982916A patent/ZA982916B/xx unknown
- 1998-04-07 AR ARP980101591A patent/AR012358A1/es not_active Application Discontinuation
- 1998-04-08 CO CO98019851A patent/CO4940403A1/es unknown
- 1998-05-16 SA SA98190065A patent/SA98190065B1/ar unknown
-
1999
- 1999-08-26 IL IL131616A patent/IL131616A/en not_active IP Right Cessation
- 1999-10-11 NO NO994946A patent/NO994946L/no unknown
- 1999-11-05 BG BG103862A patent/BG65188B1/bg unknown
-
2000
- 2000-07-26 HK HK00104658A patent/HK1027023A1/xx not_active IP Right Cessation
-
2009
- 2009-01-07 JP JP2009001631A patent/JP5188994B2/ja not_active Expired - Fee Related
-
2012
- 2012-11-14 IL IL223035A patent/IL223035A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR012358A1 (es) | Formulaciones de liberacion prolongada de derivados de eritromicina y su uso para la manufactura de un medicamento | |
BR0010485A (pt) | Formulações de derivados de eritromicina de liberação prolongada | |
CO5170471A1 (es) | Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio | |
CO5190672A1 (es) | Composicion para la dosificacion oral, de disolucion instantanea | |
AR039744A1 (es) | Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada | |
HUP0302319A2 (hu) | Gyógyszerkészítmények gyógyászati hatóanyagok szájon át történő bejuttatására | |
UY27908A1 (es) | Formulaciones y formas de dosificación para la administración controlada de topiramato | |
CR7654A (es) | Una combinacion de azelatina y esteroides | |
AR020001A1 (es) | COMPUESTOS ACTIVADORES DE hPPARGAMMA Y hPPARALFA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN, METODO PARA EL TRATAMIENTO Y/O PREVENCION DE UNAENFERMEDAD MEDIADA POR LOS MISMOS, Y SU USO PARA LA ELABORACION DE UN MEDICAMENTO | |
WO2004069198A3 (en) | Sugar-free oral transmucosal solid dosage forms and uses thereof | |
EE200100505A (et) | Modifitseeritud tärklise kasutamine hüdrofiilses kontrollitud vabanemisega preparaadis, hüdrofiilnekontrollitud vabanemisega preparaat, selle valmistamismeetod ja kasutamine ning ravimvorm | |
CY1106072T1 (el) | Φαρμακευτικη μορφη δοσης παρατεταμενης αποδεσμευσης απο του στοματος | |
AR035195A1 (es) | Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento | |
AR018862A1 (es) | Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion | |
HUP0402154A2 (hu) | Metformint és glibenklamidot tartalmazó gyógyászati készítmény II-es típusú diabetes mellitus kezelésére | |
WO2008142572A3 (en) | Controlled release tablet formulation containing magnesium aluminometasilicate | |
DE60313359D1 (de) | Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate | |
AR022589A1 (es) | UNA CÁPSULA QUE COMPRENDE UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL, UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL Y EL USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER | |
AR034813A1 (es) | Composiciones farmaceuticas y uso de las mismas | |
ES2130081B1 (es) | Comprimido de maleato de trimebutina con recubrimiento laminar. | |
AR032783A1 (es) | Una composicion farmaceutica para la administracion oral de un compuesto activo y un procedimiento para prepararla | |
CR6834A (es) | Complejos y composiciones de medicamentos macromoleculares que contienen lo mismo | |
HUP0402178A2 (hu) | 5 HT1 antagonista hatóanyagot tartalmazó gyógyszerkészítmény | |
AR035946A1 (es) | Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos | |
AR043370A1 (es) | Composiciones farmaceuticas de administracion oral y metodos para evitar la interaccion alimento -droga |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |